[go: up one dir, main page]

WO2011059733A3 - Use of lipoic acid in cell transplantation - Google Patents

Use of lipoic acid in cell transplantation Download PDF

Info

Publication number
WO2011059733A3
WO2011059733A3 PCT/US2010/054451 US2010054451W WO2011059733A3 WO 2011059733 A3 WO2011059733 A3 WO 2011059733A3 US 2010054451 W US2010054451 W US 2010054451W WO 2011059733 A3 WO2011059733 A3 WO 2011059733A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipoic acid
transplantation
fat
cell transplantation
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/054451
Other languages
French (fr)
Other versions
WO2011059733A2 (en
Inventor
William G. Austen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of WO2011059733A2 publication Critical patent/WO2011059733A2/en
Publication of WO2011059733A3 publication Critical patent/WO2011059733A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

The present invention provides lipoic acid or derivatives thereof for use in graft stabilization of fat grafts. Mixing of lipoic acid or a derivative thereof with adipocytes or adipose tissue to be transplanted into a subject leads to more succesful fat transplantation in soft tissue augmentation or reconstruction. Such methods may also be used in the transplantation of adult stem cells or other cells derived from fat tissue. Other agents such as antioxidants, vitamins, pharmaceutical agents, or osmotic protectants may also be added to the lipoic acid/cell compositions for cell transplantation.
PCT/US2010/054451 2009-10-29 2010-10-28 Use of lipoic acid in cell transplantation Ceased WO2011059733A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25597609P 2009-10-29 2009-10-29
US61/255,976 2009-10-29

Publications (2)

Publication Number Publication Date
WO2011059733A2 WO2011059733A2 (en) 2011-05-19
WO2011059733A3 true WO2011059733A3 (en) 2011-09-29

Family

ID=43992307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054451 Ceased WO2011059733A2 (en) 2009-10-29 2010-10-28 Use of lipoic acid in cell transplantation

Country Status (1)

Country Link
WO (1) WO2011059733A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245765B (en) 2008-10-21 2015-01-07 通用医院公司 cell transplantation
BR112013002859B1 (en) 2010-08-06 2020-10-06 The General Hospital Corporation D/B/A Massachusetts General Hospital METHOD AND APPARATUS FOR CELL TREATMENT
WO2014152629A1 (en) * 2013-03-15 2014-09-25 Miller Leonard B Combination therapy to improve soft tissue healing, fat graft healing, endochondral bone healing and osteointegration
WO2019124609A1 (en) * 2017-12-22 2019-06-27 경상대학교병원 Pharmaceutical composition containing alpha-lipoic acid as active ingredient for preventing or treating sialadenitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20060182725A1 (en) * 2002-11-21 2006-08-17 Isolagen Technologies, Inc., A Delaware Corporation Treatment of tissue with undifferentiated mesenchymal cells
US20070110731A1 (en) * 2005-11-16 2007-05-17 Riley Patricia A Integument Cell Regeneration Formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20060182725A1 (en) * 2002-11-21 2006-08-17 Isolagen Technologies, Inc., A Delaware Corporation Treatment of tissue with undifferentiated mesenchymal cells
US20070110731A1 (en) * 2005-11-16 2007-05-17 Riley Patricia A Integument Cell Regeneration Formulation

Also Published As

Publication number Publication date
WO2011059733A2 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
WO2010047793A3 (en) Cell transplantation
WO2007080591A3 (en) Adult stem cell-derived connective tissue progenitors for tissue engineering
WO2009085969A3 (en) Compositions and methods to promote implantation and engrafment of stem cells
MX2009014273A (en) Methods and compositions for optimized expansion and implantation of mesenchymal stem cells.
WO2009002456A3 (en) Methods and compositions relating to progenitor cells
WO2010021714A3 (en) Improved cell composition and methods of making the same
MX2010010236A (en) Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents.
EP4403197A3 (en) Injectable formulations for organ augmentation
WO2009142770A3 (en) Compositions and methods for generating musculoskeletal tissue
WO2013005110A3 (en) Synthetic scaffolds and organ and tissue transplantation
EP2603227A4 (en) Improved hematopoietic stem and progenitor cell therapy
WO2010017562A3 (en) Induced pluripotent stem cells
MX2015017298A (en) Lipofilling with ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling or for facial filling and/or rejuvenation.
MY159971A (en) Multipotent/pluripotent cells and methods
GEP20146053B (en) Compounds expanding hematopoietic stem cells
WO2009152084A3 (en) Adipose tissue-derived stem cells for veterinary use
MX352823B (en) Protein formulations containing amino acids.
WO2012019103A3 (en) System and apparatus for cell treatment
WO2012012737A3 (en) Stable tregs and related materials and methods
WO2012048010A3 (en) Compositions of adult organ stem cells and uses thereof
PH12013502215A1 (en) Beautiful-skin-promoting agent and use thereof
PH12013501773A1 (en) Nutritional compositions for increasing arginine levels and methods of using same
SG10201901713RA (en) Extracellular matrix compositions
ZA201504284B (en) Solution for preserving vascular conduits
MY159492A (en) Solid pharmaceutical formulation with delayed release

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10830443

Country of ref document: EP

Kind code of ref document: A2